Japan Blood Cancer Diagnostics Market Size & Outlook

The blood cancer diagnostics market in Japan is expected to reach a projected revenue of US$ 544.9 million by 2030. A compound annual growth rate of 7.5% is expected of Japan blood cancer diagnostics market from 2025 to 2030.
Revenue, 2024 (US$M)
$352.5
Forecast, 2030 (US$M)
$544.9
CAGR, 2025 - 2030
7.5%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan blood cancer diagnostics market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan blood cancer diagnostics market highlights

  • The Japan blood cancer diagnostics market generated a revenue of USD 352.5 million in 2024 and is expected to reach USD 544.9 million by 2030.
  • The Japan market is expected to grow at a CAGR of 7.5% from 2025 to 2030.
  • In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
  • Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.

Blood cancer diagnostics market data book summary

Market revenue in 2024USD 352.5 million
Market revenue in 2030USD 544.9 million
Growth rate7.5% (CAGR from 2025 to 2030)
Largest segmentAssay kits and reagents
Fastest growing segmentAssay Kits and Reagents
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationInstruments, Assay Kits and Reagents

Other key industry trends

  • In terms of revenue, Japan accounted for 3.3% of the global blood cancer diagnostics market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China blood cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,612.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Blood Cancer Diagnostics Market Companies

Name Profile # Employees HQ Website
SkylineDx View profile 11-50 Rotterdam, Zuid-Holland, The Netherlands, Europe http://www.skylinedx.com/
Invivoscribe, Inc. View profile 251-500 San Diego, California, United States, North America https://www.invivoscribe.com
Abbott View profile - - -
QIAGEN View profile - - -
Danaher Corporation View profile - - -
Adaptive Biotechnologies View profile 501-1000 Seattle, Washington, United States, North America http://adaptivebiotech.com
Sophia Genetics SA View profile 449 La Pièce 12, Rolle, Switzerland, CH-1180 https://www.sophiagenetics.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Quest Diagnostics Inc View profile 48000 500 Plaza Drive, Secaucus, NJ, United States, 07094 https://www.questdiagnostics.com

Japan blood cancer diagnostics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.


Assay kits and reagents was the largest segment with a revenue share of 72.45% in 2024. Horizon Databook has segmented the Japan blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.


Japan blood cancer diagnostics market is expected to witness rapid expansion, propelled by the government's substantial investments aimed at combating the country's escalating cancer burden. This surge in cancer prevalence is due to Japan's rapidly aging demographics, with one of the highest median ages worldwide at 44 years.

Distinguishing itself from neighboring countries, Japan has implemented nationwide cancer screening initiatives, a proactive measure to address its rising cancer prevalence. For instance, in January 2021, Illumina partnered with Otsuka Pharmaceuticals to develop and commercialize an IVD genomic profiling testing kit for patients in Japan with blood cancers.

Such partnerships are anticipated to drive market growth in the region. In another development, in May 2022, Hitachi High-Tech formed a strategic partnership with Invivoscribe, a leading provider of blood cancer testing kits and services, by investing in the company through a minority shareholding.

Reasons to subscribe to Japan blood cancer diagnostics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan blood cancer diagnostics market databook

  • Our clientele includes a mix of blood cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Japan blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan blood cancer diagnostics market size, by product, 2018-2030 (US$M)

Japan Blood Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)

Japan blood cancer diagnostics market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online